Is Vertex Pharmaceuticals Inc Gaining or Losing Market Support? - Vertex Pharmaceuticals ( NASDAQ:VRTX )
Vertex Pharmaceuticals Inc's ( NYSE:VRTX ) short interest as a percent of float has risen 17.95% since its last report. According to exchange reported data, there are now 4.13 million shares sold short, which is 1.84% of all regular shares that are available for trading.
1 Incredible Reason to Buy Vertex Pharmaceuticals Stock in November
It's a good idea to go against the current market sentiment on this one.
1 Underrated Stock That Could Soar by 58%, According to Wall Street
This biotech has already made impressive contributions to medicine, and it could make more. But does that make it a buy?
My 3 Favorite Stocks to Buy Right Now
These stocks stand above the rest.
Can NTLA Stock Bounce Back in 2026 After Recent Pipeline Setbacks?
Intellia faces FDA clinical holds on key ATTR studies as it readies crucial HAE data in 2026, making lonvo-z pivotal for its near-term outlook.
CRISPR Therapeutics's Options Frenzy: What You Need to Know - CRISPR Therapeutics ( NASDAQ:CRSP )
Whales with a lot of money to spend have taken a noticeably bearish stance on CRISPR Therapeutics. Looking at options history for CRISPR Therapeutics ( NASDAQ:CRSP ) we detected 13 trades.
CRSP Posts Narrower-Than-Expected Loss in Q3, Sales Miss Estimates
CRISPR Therapeutics posts a narrower-than-expected Q3 loss, trims R&D spend, and advances late-stage and next-gen gene-editing programs.
CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering
-Data presented in a late-breaking presentation at the American Heart Association ( AHA ) Scientific Sessions ...
FDA Fast-Tracks 6 More Drugs - Obesity And Cancer Drugs Included - Johnson & Johnson ( NYSE:JNJ ) , GSK ( NYSE:GSK )
On Thursday, the U.S. Food and Drug Administration ( FDA ) announced six additional awardees under the Commissioner's National Priority Voucher ( CNPV ) pilot program. Boehringer Ingelheim Pharmaceuticals Inc.'s Hernexeos ( Zongertinib ) for HER2 lung cancer.
Vertex Pharmaceuticals Incorporated ( VRTX ) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Moderna Q3 Earnings Beat, Stock Up on Revised '25 Spending Plans
MRNA posts narrower-than-expected Q3 loss and lifts liquidity outlook for 2025, as cost cuts and revised spending plans boost investor sentiment ...
CRISPR Therapeutics Options Trading: A Deep Dive into Market Sentiment - CRISPR Therapeutics ( NASDAQ:CRSP )
Financial giants have made a conspicuous bearish move on CRISPR Therapeutics. Our analysis of options history for CRISPR Therapeutics ( NASDAQ:CRSP ) revealed 9 unusual trades. Delving into the details, we found 33% of traders were bullish, while 44% showed bearish tendencies.
VRTX's New Drugs Performance Mixed in Q3: Can Their Sales Improve?
VRTX's new drugs deliver a mixed Q3 performance. Alyftrek sales surge. Journavx and Casgevy lag expectations but show promise.
Vertex Q3 Earnings Beat, Stock Down as Casgevy Sales Disappoint
VRTX tops Q3 earnings and revenue estimates on strong Trikafta and Alyftrek sales, but shares slip as Casgevy sales disappoint.
Prediction: 2 Stocks That Will Be Worth More Than SoundHound AI 2 Years From Now
It is a smart strategy to diversify your portfolio by investing in high-quality companies built on proven technologies.
Vertex Pharmaceuticals ( VRTX ) Q3 Earnings and Revenues Top Estimates
Vertex (VRTX) delivered earnings and revenue surprises of +5.49% and +1.14%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Vertex Pharmaceuticals Likely To Report Higher Q3 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call - Vertex Pharmaceuticals ( NASDAQ:VRTX )
Vertex Pharmaceuticals Incorporated ( NASDAQ:VRTX ) will release earnings results for the first quarter, after the closing bell on Monday, Nov. 3. Analysts expect the Boston, Massachusetts-based company to report quarterly earnings at $4.58 per share, up from $4.38 per share in the year-ago ...
Should CRSP Stock Be in Your Portfolio Pre-Q3 Earnings?
CRISPR Therapeutics is likely to witness an earnings beat as Casgevy sales climb and new CAR-T and in-vivo programs advance.
2 Healthcare Stocks for Individual Investors With a 20-Year Time Horizon
These healthcare stocks are making strides in very important ways.
Inflation-Proof Investing: Which Growth Stock Will Double Your Money in 6 Years?
These are great picks with or without soaring inflation.
My Top Growth Stock to Buy in November
This stock isn't bulletproof. But it should be a big winner over the coming years.
Rigel Gears Up to Report Q3 Earnings: Here's What to Expect
RIGL's rising Tavalisse sales, along with incremental sales from Rezlidhia and Gavreto, could power another earnings beat in the quarter to be reported.
Rigel Gears Up to Report Q3 Earnings: Here's What to Expect
RIGL's rising Tavalisse sales, along with incremental sales from Rezlidhia and Gavreto, could power another earnings beat in the quarter to be reported.
Here's How Much $100 Invested In Vertex Pharmaceuticals 15 Years Ago Would Be Worth Today - Vertex Pharmaceuticals ( NASDAQ:VRTX )
Vertex Pharmaceuticals ( NASDAQ:VRTX ) has outperformed the market over the past 15 years by 5.91% on an annualized basis producing an average annual return of 18.0%. Currently, Vertex Pharmaceuticals has a market capitalization of $107.16 billion.
Vertex Pharmaceuticals ( VRTX ) Stock Moves -1.23%: What You Should Know
In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $417.21, denoting a -1.23% move from the preceding trading day.
Zoetis Gears Up to Report Q3 Earnings: Here's What to Expect
ZTS is poised for another earnings beat as rising demand for companion animal products like Simparica Trio and Apoquel drives expected Q3 revenue growth.
Amgen's Q3 Earnings in the Cards: Here's What to Expect
Amgen's Q3 results are on deck, with growth from newer drugs offset by biosimilar competition and pricing pressures.
Exploring Analyst Estimates for Vertex ( VRTX ) Q3 Earnings, Beyond Revenue and EPS
Get a deeper insight into the potential performance of Vertex (VRTX) for the quarter ended September 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Vertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards?
Strong Trikafta/Kaftrio demand, along with contributions from Alyftrek, Casgevy and Journavx, may have helped VRTX outperform in the third quarter.
Will Ultragenyx ( RARE ) Report Negative Q3 Earnings? What You Should Know
Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
If I Could Only Buy 2 Stocks in the Last Quarter of 2025, I'd Pick These
These two have been neglected by Wall Street too much.
Step Therapy Shifts and Pipeline Momentum Reshape the Membranous Nephropathy Treatment Landscape, according to Spherix Global Insights
EXTON, PA, Oct. 28, 2025 ( GLOBE NEWSWIRE ) -- The membranous nephropathy ( MN ) treatment paradigm is on the brink of transformation, with physicians signaling strong interest in novel mechanisms of action and shifting away from legacy regimens, according to Spherix Global Insights' recently ...
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Vertex Pharmaceuticals ( VRTX ) Earnings Expected to Grow: Should You Buy?
Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Prediction: Vertex Pharmaceuticals Will Be Worth More Than Pfizer by 2030
Vertex appears to be by far the better buy right now.
The Best Stocks to Invest $50,000 In Right Now
There's no guarantee that any stock will deliver positive returns. But the odds look good for these three.
Vertex Pharmaceuticals Incorporated ( VRTX ) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.
Climb Bio Names Adam Villa as SVP, Technical Operations and Ashley Jones as SVP, People & Workforce Strategy
WELLESLEY HILLS, Mass., Oct. 21, 2025 ( GLOBE NEWSWIRE ) -- Climb Bio, Inc. ( Nasdaq: CLYM ) , a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced that it has strengthened its leadership team with the appointments of Adam Villa as Senior ...
Can NTLA's In Vivo Pipeline Aid Long-Term Growth Amid Competition?
Intellia banks on its late-stage gene-editing therapies, lonvo-z and nex-z, that could define its long-term growth phase in the gene editing space.
2 Growth Stocks to Invest $1,000 in Right Now
These companies have a habit of beating the market, and they are far from having peaked.
Vertex Pharmaceuticals ( VRTX ) Outpaces Stock Market Gains: What You Should Know
The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $416.81, representing a +2.01% change from its previous close.
2 Soaring Cathie Wood Stocks to Buy and Hold
These companies' market-beating fuel hasn't run out yet.
Vera Therapeutics' Lead Kidney Drug Poised For 2026 Launch In Multi-Billion-Dollar Market - Vera Therapeutics ( NASDAQ:VERA )
BofA Securities initiated coverage on Vera Therapeutics, Inc. ( NASDAQ:VERA ) , ahead of a key catalyst in 2026 for its lead drug, atacicept, for kidney disease.
New to Growth Stocks? Here's 1 Every Investor Should Have on Their Radar.
CRISPR Therapeutics is a promising mid-cap biotech stock with an approved product in its portfolio.
Vertex Pharmaceuticals ( VRTX ) Stock Sinks As Market Gains: What You Should Know
In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $407.9, denoting a -1.05% move from the preceding trading day.
2 Unstoppable Growth Stocks to Buy During a Market Crash
Here are two smart ways to prepare for the next market downturn.
Here's How Much $100 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth Today - Vertex Pharmaceuticals ( NASDAQ:VRTX )
Vertex Pharmaceuticals ( NASDAQ:VRTX ) has outperformed the market over the past 10 years by 1.56% on an annualized basis producing an average annual return of 14.01%. Currently, Vertex Pharmaceuticals has a market capitalization of $104.87 billion.
4 Healthcare Stocks to Buy Now
As investors crowd into AI names at record highs, these three healthcare stocks offer more compelling valuations.
CRISPR Therapeutics Presents New Preclinical Data for CTX460™ Demonstrating In Vivo Gene Correction of Alpha-1 Antitrypsin Deficiency ( AATD ) Utilizing Novel SyNTase™ Editing Platform
-Preclinical data presented at the European Society of Gene and Cell Therapy ( ESGCT ) highlight a potential ...
